GlassScriptPhysician profile
Isaac B Tunnell
NPI 1164670634
$10,494.44
in general payments reported to CMS, 2019-2025
29 companies · $2,310 in 2025
The $2,310 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,186 · 2022: $1,897 · 2023: $2,072 · 2024: $2,030 · 2025: $2,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,411.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $2,031.34 | 2021-2025 | Belbuca, Nucynta, Xtampza |
| Scilex Pharmaceuticals INC. | $1,469.30 | 2021-2025 | Ztlido |
| Abbvie INC. | $1,225.39 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $884.66 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $834.14 | 2021-2025 | Relistor |
| Pfizer INC. | $709.41 | 2021-2025 | |
| Indivior INC. | $475.86 | 2022-2025 | Sublocade |
| Braeburn INC. | $311.26 | 2023-2025 | Brixadi |
| Redhill Biopharma INC. | $293.24 | 2021-2023 | Movantik, Aemcolo, Talicia |
| Almatica Pharma LLC | $277.68 | 2021-2023 | Gralise |
| Idorsia Pharmaceuticals US INC | $239.41 | 2022-2025 | Quviviq, Quviviq |
| Orexo US, INC. | $210.73 | 2023-2025 | Zubsolv |
| Biodelivery Sciences International, INC. | $180.33 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $176.31 | 2022 | |
| Axsome Therapeutics, INC. | $172.65 | 2023-2025 | Sunosi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $156.96 | 2022-2025 | Vyepti |
| Forte Bio-Pharma LLC | $125.35 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Ibsa Pharma INC. | $110.44 | 2021-2025 | Tirosint, Licart, Flector |
| Arbor Pharmaceuticals, INC. | $108.46 | 2021-2022 | |
| Protega Pharmaceutials INC | $94.35 | 2024 | Roxybond |
| Abbott Laboratories | $83.58 | 2021-2023 | Freestyle Libre 2 |
| Lilly USA, LLC | $71.73 | 2021-2023 | Reyvow, Emgality |
| Azurity Pharmaceuticals, INC. | $65.37 | 2023-2025 | Horizant, Horizant |
| Nevro Corp. | $62.59 | 2022 | |
| Grt US Holding, INC. | $50.39 | 2021-2022 | |
| Boston Scientific Corporation | $24.34 | 2025 | General - Pain Management |
| Averitas Pharma INC. | $20.15 | 2025 | Qutenza |
| Uswm, LLC | $15.15 | 2021 | |
| Medtronic, INC. | $13.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Tunnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.